Clinical Trials Logo

Open-Angle Glaucoma clinical trials

View clinical trials related to Open-Angle Glaucoma.

Filter by:

NCT ID: NCT00061529 Completed - Ocular Hypertension Clinical Trials

A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT00047593 Completed - Ocular Hypertension Clinical Trials

Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98

Start date: January 2000
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate safety and efficacy of two different IOP lowering medications after twelve months of treatment in Japanese subjects.

NCT ID: NCT00047541 Completed - Ocular Hypertension Clinical Trials

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70

Start date: February 2001
Phase: Phase 3
Study type: Interventional

To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.

NCT ID: NCT00047528 Completed - Ocular Hypertension Clinical Trials

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41

Start date: January 2001
Phase: Phase 3
Study type: Interventional

To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.

NCT ID: NCT00047515 Completed - Ocular Hypertension Clinical Trials

Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69

Start date: January 2001
Phase: Phase 3
Study type: Interventional

To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.

NCT ID: NCT00001161 Completed - Ocular Hypertension Clinical Trials

Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens

Start date: July 1977
Phase: N/A
Study type: Observational

This study will investigate congenital or developmental eye abnormalities that affect the iris, cornea and lens, and are usually accompanied by elevated pressure within the eye. These disorders can cause vision loss, and the increased eye pressure can lead to glaucoma, a condition that may also cause loss of eyesight. Patients with eye anterior chamber eye disease, such as Axenfeld's syndrome, Rieger's anomaly, Peter's anomaly, iridocorneal endothelial syndrome, megalocornea, ocular hypertension, and others, are eligible for this study. Participants will have a medical examination, family history, and comprehensive eye examination. Tests and procedures may include photographs of the cornea, iris, and the structure through which fluid that normally circulates behind the cornea drains out of the eye. Some patients may undergo indentation tonography to measure how easily this fluid drains. In this procedure, the patient lies on an examination table and both eyes are numbed with eye drops. A small instrument (tonometer) is placed on the surface of one eye, and with the other eye, the patient looks at an overhead light. Other tests may include photographs of the back of the eye and ultrasound imaging of the structures of the eye. A blood sample may be drawn to study the genetic disorder responsible for the disease. Patients will have follow-up examinations every 6 months for the duration of the study. Medical or surgical therapy will be recommended, as appropriate, for patients who develop elevated eye pressure or vision loss.

NCT ID: NCT00000144 Completed - Open-Angle Glaucoma Clinical Trials

Glaucoma Laser Trial (GLT) Glaucoma Laser Trial Followup Study (GLTFS)

Start date: January 1984
Phase: Phase 3
Study type: Interventional

To compare the safety and long-term efficacy of argon laser treatment of the trabecular meshwork with standard medical treatment for primary open-angle glaucoma.